Wolverine Legal Status, FDA 503A Category, and Compounding Access
FDA's page, current as of April 22, 2026, places both peptides in the BPC-157 TB-500 blend under "Bulk drug substances nominated but withdrawn," rather than in Category 2; the withdrawal does not say whether a pharmacy may compound them.
Wolverine legal status: where BPC-157 TB-500 access stands now and where it is heading
The most important fact about the Wolverine legal status is also the least finished one: FDA has not said what its current record means for compounding either peptide in the BPC-157 TB-500 blend. FDA's Pharmacy Compounding Advisory Committee (PCAC) met on July 23-24, 2026, and both BPC-157 and TB-500 were on its published agenda as bulk drug substances "being considered for inclusion on the 503A Bulks List" [11][12]. FDA staff had proposed against adding them — a step in the process, not a decision. As of September 2026 FDA has published no record of the committee's votes, so no outcome should be read into the meeting.
What is on the record is the history. FDA placed both constituents in 503A "Category 2" with its September 29, 2023 update, but its current page lists their nominations as withdrawn while retaining the agency's stated safety concerns [13][14]. Category 2 substances are not covered by FDA's enforcement-discretion policy for 503A compounding, but FDA has not said whether that limit still applies once a nomination is withdrawn, so what a compounding pharmacy may do with these two peptides is a question the agency has left open [13]. Neither peptide is an FDA-approved drug, and the blend has no approved therapeutic indication. This page is general information about the regulatory landscape, not medical or legal advice.
Both nominations were withdrawn — and FDA staff proposed against listing both before the July 2026 PCAC meeting
There is no component carve-out in the BPC-157 TB-500 blend. Both legs are in the same regulatory position.
BPC-157 (which FDA evaluated as "BPC-157 (free base)" and "BPC-157 acetate") was placed in Category 2 effective September 29, 2023, with FDA citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [13]. TB-500 — which FDA lists as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — was placed in Category 2 on the same date, with FDA citing potential immunogenicity for certain routes and a lack of important safety information [14]. FDA's own list entry establishes the relationship between the marketed name and the fragment: TB-500 is the LKKTETQ fragment associated with Thymosin Beta-4 [14].
Both went before the same review. The July 23-24, 2026 PCAC agenda listed both BPC-157 and TB-500 (alongside other peptides) as candidates being considered for the 503A Bulks List [11][12]. A PCAC discussion is advisory; it informs FDA, but it is not itself a listing decision. The honest read is an open file, not a verdict: the meeting has come and gone, FDA has not published how the committee came down, and nothing about 503A access for these peptides carries a dated outcome.
How legally compounded peptide access works
Setting aside any single substance, it helps to understand how lawful compounded-medication access works in the United States. Drug compounding is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, performed pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight [15].
The lawful pathway runs in a fixed order. First, a patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [16]. Telehealth here is simply one front-end channel to that evaluation and prescription; it does not change which substances may be compounded and does not remove the need for a legitimate prescriber-patient relationship and a valid prescription [16]. Second, if appropriate and lawful, the prescriber issues a valid, patient-specific prescription. Third, the prescription is dispensed by a state-licensed 503A compounding pharmacy, or sourced for office or batch use from an FDA-registered 503B outsourcing facility [16].
The critical caveat sits at the ingredient level. A compounder may use a bulk drug substance only if it is the subject of an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list [15]. A substance FDA keeps in Category 2 for significant safety risks falls outside its policy for routine 503A compounding [13]. Both nominations were withdrawn by their sponsors, and FDA's current page no longer lists either leg of the blend in Category 2; FDA has not explained what that record permits a 503A pharmacy to do [13][14]. This is general regulatory information, not a route to obtain any restricted substance.
Is Wolverine (BPC-157 + TB-500) legal?
Neither peptide in the blend is an FDA-approved drug, and the blend has no approved therapeutic indication. FDA placed both BPC-157 and TB-500 in 503A "Category 2" on September 29, 2023, but its current page records that the nominations were later withdrawn; FDA has not explained whether pharmacies may compound them [13][14]. Both also appeared on the July 23-24, 2026 PCAC agenda, and FDA has not published the committee's votes from that meeting [11].
Can you get BPC-157 from a compounding pharmacy?
There is no clean yes or no. FDA placed BPC-157 in 503A "Category 2" effective September 29, 2023; the current FDA page instead records that the nomination was withdrawn, and FDA has not stated whether 503A compounders may use it [13]. BPC-157 was on the July 23-24, 2026 PCAC agenda as a 503A bulks-list candidate, after FDA staff had proposed against adding it, and the agency has released no record of what the committee decided [11][13].
What is the FDA 503A status of Wolverine (BPC-157 + TB-500)?
Both components were placed in 503A "Category 2" — substances FDA identified as potentially presenting significant safety risks — effective September 29, 2023; FDA's page, current as of April 22, 2026, shows both nominations withdrawn instead, with the safety concerns still printed beside them [13][14]. Category 2 substances fall outside FDA's enforcement-discretion policy, and FDA has not said whether a withdrawn nomination is treated the same way [13]. Both BPC-157 and TB-500 were on the July 23-24, 2026 PCAC agenda as candidates being considered for the 503A Bulks List; no record of the committee's votes has been published [11][12].
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use, and both were 503A "Category 2" bulk substances before their nominations were withdrawn [13][14]. Both are also WADA-prohibited — BPC-157 under S0 non-approved substances; TB-500 / thymosin beta-4 under prohibited peptide and tissue-repair categories [10]. The blend has no approved therapeutic indication.